Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 13/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26466205 | 0.94 | CACNA1H (0.68) | CACNA1HKDM4EALDH1A1KMT2AEPHX2 | |
| SCHEMBL26466776 | 0.89 | CACNA1H (0.56) | CACNA1HKDM4EALDH1A1KMT2AEPHX2 | |
| SCHEMBL26466764 | 0.89 | CACNA1H (0.55) | CACNA1HKDM4EALDH1A1KMT2A | |
| SCHEMBL26466775 | 0.87 | CACNA1H (0.54) | CACNA1HKDM4EALDH1A1KMT2A | |
| SCHEMBL26466763 | 0.86 | CACNA1H (0.51) | CACNA1HKDM4EALDH1A1KMT2A | |
| SCHEMBL26465830 | 0.84 | CACNA1H (0.73) | CACNA1HKDM4EALDH1A1KMT2A | |
| SCHEMBL26498849 | 0.82 | CACNA1H (1.00) | CACNA1HKDM4EALDH1A1KMT2A | |
| SCHEMBL26466911 | 0.81 | CACNA1H (0.46) | CACNA1HKDM4EALDH1A1EPHX2 | |
| SCHEMBL26463801 | 0.80 | CACNA1H (0.71) | CACNA1HKDM4EALDH1A1KMT2A | |
| SCHEMBL26464310 | 0.79 | CACNA1H (0.92) | CACNA1HKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192669-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |